EUVIMEDEUVIMED entdecken
Crossref

Dual COX‐2/5‐LOX Inhibition by Novel Thymol Derivatives: From Molecular Modeling to In Vitro Validation

Alice Romeo, Silvia Pezzola, Francesca Valentini, Federico Iacovelli, Mattia Falconi, Federica Sabuzi iD

ChemBioChem · 2026

DOI: 10.1002/cbic.202500706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2026. Verfasst von Alice Romeo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133, Rome, Italy. Hauptthemen laut MEDLINE: Thymol, Lipoxygenase Inhibitors, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LOX) inhibitors constitute safer alternatives to classical nonsteroidal anti‐inflammatory drugs, widely used to effectively manage inflammation. In this article, molecular docking and molecular dynamics simulations guide the synthesis of novel thymol derivatives that interact with both COX‐2 and 5‐LOX active sites. Ligands are designed with the aim of improving thymol bioactivity, selectivity, stability, as well as pharmacokinetic properties. Therefore, –Br, –F, and –CF 3 inclusion on thymol is here evaluated, screening COX‐2 and 5‐LOX interactions with thymol ( T ), 4‐fluorothymol ( FT ), 4‐bromothymol ( BT ), isopropyl thymyl succinate ( T1 ), 1,1,1,3,3,3‐hexafluoroisopropyl thymyl succinate ( T2 ), and 1′,1′,1′,3′,3′,3′‐hexafluoroisopropyl 4‐(4′’‐thymyl)‐4‐oxobutanoate ( T3 ). Molecular modeling reveals that the estimated ligands can establish favorable interactions with both COX‐2 and 5‐LOX active pockets, highlighting T1 –T3 as the most promising compounds. In vitro assays identify T3 as the most active COX‐2 inhibitor, while T2 results as the most effective ligand for 5‐LOX. Interestingly, cavity analysis of the COX‐2 entry site reveals that T3 insertion is favored over T1 and T2 due to its greater polarity, conferred by the presence of a free phenolic group (OH) able to establish H‐bonds with surrounding residues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThymolLipoxygenase InhibitorsCyclooxygenase 2Cyclooxygenase 2 InhibitorsArachidonate 5-LipoxygenaseHumansMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipMolecular Structure

Stichwörter der Autor:innen

5‐LOXCOX‐2molecular dockingmolecular dynamicsthymol derivatives

Substanzen

ThymolLipoxygenase InhibitorsCyclooxygenase 2Cyclooxygenase 2 InhibitorsArachidonate 5-Lipoxygenase

Autor:innen und Institutionen

  • Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133, Rome, Italy.
  • Department of Chemical Science and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133, Rome, Italy.

ORCID-Profile: Federica Sabuzi

Zitieren

APA

Romeo, A., Pezzola, S., Valentini, F., Iacovelli, F., Falconi, M., & Sabuzi, F. (2026). Dual COX‐2/5‐LOX Inhibition by Novel Thymol Derivatives: From Molecular Modeling to In Vitro Validation. ChemBioChem. https://doi.org/10.1002/cbic.202500706

Vancouver

Romeo A, Pezzola S, Valentini F, Iacovelli F, Falconi M, Sabuzi F. Dual COX‐2/5‐LOX Inhibition by Novel Thymol Derivatives: From Molecular Modeling to In Vitro Validation. ChemBioChem. 2026. doi:10.1002/cbic.202500706

BibTeX
@article{Romeo2026,
  author = {Romeo, Alice and Pezzola, Silvia and Valentini, Francesca and Iacovelli, Federico and Falconi, Mattia and Sabuzi, Federica},
  title = {Dual COX‐2/5‐LOX Inhibition by Novel Thymol Derivatives: From Molecular Modeling to In Vitro Validation},
  journal = {ChemBioChem},
  year = {2026},
  doi = {10.1002/cbic.202500706}
}
Kostenlos starten →